Issuer Client News

News & Events

Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

  • Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently
  • Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value

FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first quarter ended March 31, 2024, and provided a corporate update.

“We are excited by the initial traction made in the limited U.S. commercial launch of our Pure-Vu® EVS Gastro and Gen 4 Colon system, which was kicked off at the end of 2023. The market acceptance of these two systems has been positive, which is evident by our doubling the number of active customers, reignited interest among several customer accounts that were inactive over the past year, as well as a growing sales pipeline of potential new customers. The most fulfilling aspect of the new system is seeing the device support emergent cases in GI bleeding and seeing how sites can adopt the technology with no onsite support. This enhanced end-user experience has resulted in 100% of fully onboarded customers now using the Pure-Vu system independently, as compared to only 25% of customers using the previous generation system. These types of engagements further show how we are now able to deliver on the potential that we always knew the Pure-Vu system could offer physicians, hospitals, and patients,” commented Mark Pomeranz, Chief Executive Officer.

First Quarter and Recent Business Highlights

  • At the end of the first quarter of 2024, the Company successfully implemented a limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system. To date, this initial phase of the rollout successfully doubled the number of active Pure-Vu customers, defined as placing an order for disposable sleeves in the six months prior to FDA approval of the new system. In addition, 100% of the established customers onboarded are now using the Pure-Vu independently, which highlights the latest generation’s easy to use design. The new Gen 4 Colon system, which features a sleeveless Flex-Channel design, is also being well-received by early-adopters, who have commented on the system’s improved handling and easy setup.
  • Announced positive data from a colonoscopy study that concluded adequate bowel cleaning can be achieved in patients with a history of inadequate bowel preparation by using the Pure-Vu System. These data were published in the peer-reviewed journal, United European Gastroenterology (UGE).
  • Received approval from the Israeli Ministry of Health, Medical Device Division (known as "AMAR") to initiate commercial sales of the Pure-Vu® EVS Colon System in Israel, one of the largest markets in the Middle East.
  • Continued to strengthen the Company’s IP portfolio with a key patent issued by the United States Patent and Trademark Office (USPTO) in the first quarter of 2024, which covers the systems and methods for cleaning a colon or other portion of the GI tract, including the optional use of sensors to detect conditions of blockage of flow of materials within an evacuation channel used to remove debris from the body; and devices and methods for purging such blockages from the evacuation channel.
  • The Company’s Board of Directors recently engaged a well-known investment bank to identify and evaluate strategic alternatives, aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value.
  • The Company’s common stock was approved for quotation on the OTCQB market starting Monday, May13, 2024, under the symbol “MOTS.”

Financial Results for the Quarter Ended March 31, 2024

The Company reported revenue of $64,000 for the first quarter of 2024, compared to $56,000 for the same period last year. Revenues were primarily derived from reorders and new customer orders of disposable sleeves.

For the three months ended March 31, 2024, the Company reported a net loss attributable to common shareholders of $7.6 million, or $0.88 per basic and diluted share, compared to a net loss attributable to common shareholders of $4.4 million, or $13.81 per basic and diluted share, for the same period last year.

During the first quarter of 2024, net cash used in operating activities and for the purchase of fixed assets was $2.0 million as compared to $4.8 million for the same period of 2023.

The Company reported $4.9 million in cash and cash equivalents as of March 31, 2024. This balance includes the fully funded credit facility with Kreos Capital, which has approximately $2.3 million due and outstanding as of March 31, 2024.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, business strategies, potential grow opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s quarterly and annual reports filed with the Securities and Exchange Commission, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share amounts)
 
    March 31,     December 31,  
    2024     2023  
    (unaudited)        
Assets                
Current assets:                
Cash and cash equivalents   $ 4,944     $ 4,958  
Accounts receivable     81       76  
Inventory, current     228       245  
Prepaid expenses and other current assets     497       478  
Total current assets     5,750       5,757  
                 
Fixed assets, net     897       992  
Inventory, non-current     251       251  
Right-of-use assets     155       210  
Other non-current assets     13       13  
Total assets   $ 7,066     $ 7,223  
                 
Liabilities and Shareholders’ Equity                
Current liabilities:                
Accounts payable and accrued expenses   $ 1,495     $ 1,842  
Operating lease liabilities - current     116       169  
Other current liabilities     66       226  
Current portion of long-term debt, net of unamortized debt discount of $4 and $108, respectively     1,632       1,033  
Total current liabilities     3,309       3,270  
                 
Long-term debt, net of unamortized debt discount of $91 and $16, respectively     669       1,239  
Operating lease liabilities - non-current     21       27  
Total liabilities     3,999       4,536  
                 
Commitments and contingent liabilities (Note 9)                
                 
Shareholders’ equity                
Common stock $0.0001 par value; 115,000,000 shares authorized; 5,210,876 and 1,547,042 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively     1       -  
Additional paid-in capital     159,398       156,905  
Accumulated deficit     (156,331 )     (154,218 )
Total shareholders’ equity     3,068       2,687  
Total liabilities and shareholders’ equity   $ 7,066     $ 7,223  


Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited, in thousands, except share and per share amounts)
             
    Three Months Ended
March 31,
 
    2024     2023  
             
Revenue   $ 64     $ 56  
                 
Operating expenses:                
Cost of revenue - sales     12       9  
Cost of revenue - impairment of inventory     -       165  
Research and development     455       1,454  
Sales and marketing     151       842  
General and administrative     1,472       1,945  
Total costs and expenses     2,090       4,415  
Loss from operations     (2,026 )     (4,359 )
                 
Gain on change in estimated fair value of contingent royalty obligation     -       220  
Finance expense, net     (80 )     (239 )
Foreign currency loss     (7 )     (8 )
                 
Net loss   $ (2,113 )   $ (4,386 )
Deemed dividends from warrant issuance     (5,508 )     -  
Net loss attributable to common shareholders   $ (7,621 )   $ (4,386 )
                 
Basic and diluted loss per common share:                
Net loss   $ (0.25 )   $ (13.81 )
Net loss attributable to common shareholders     (0.88 )     (13.81 )
Weighted average number of common shares outstanding, basic and diluted     8,613,204       317,547  

Investor Contact:

Troy Williams
LifeSci Advisors
(518) 221-0106
twilliams@lifesciadvisors.com

Primary Logo

Source: Motus GI Holdings, Inc.

Brokerage and investment advisory products and services, are offered through Aegis Capital Corp, a member of FINRA and SIPC. Insurance products are made available through, ACC General Agency, a licensed insurance agency. For those persons inquiring from states where a specific associate is not currently securities and/or insurance licensed, the associate will not transact business in that state or provide follow-up individual responses, until after the associate obtains the appropriate registration in the applicable state.

The information provided should not be relied upon in isolation for the purpose of making an investment decision. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. Prior to making any investment or financial decision, an investor should seek advice from a financial, legal, tax and other professional that consider all of the particular facts and circumstances of an investor's situation. The opinions expressed and material provided are for information purposes only and is not an offer, recommendation, or solicitation of any product, strategy or transaction. Any views, strategies or products discussed may not be appropriate or suitable for all individuals and are subject to risks.

Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

Check the background of your financial professional on FINRA's BrokerCheck

Form CRS and General Disclosures

Aegis Risk Disclosures